Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine

Berlanga, Carlos; Ortega‐Soto, Hector A.; Ontiveros, Martha; Sentíes, Héctor

doi:10.1016/0165-1781(92)90029-3

Cited by 59 publications

(31 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While there have been no studies on this precise question with regards to combining SAMe with SSRIs, in a 2-wk, double-blind, placebo-controlled study of SAMe augmentation of imipramine in 40 MDD patients Berlanga et al (2001) reported that depressive symptoms decreased earlier by the end of week 2 in the SAMe group than the placebo group. In parallel, our group had reported that 55 % of 195 MDD patients treated with parenteral SAMe responded by day 15 of treatment, while a statistically significant drop in HAMD scores from baseline was noted even by day 7 (Fava et al, 1995).…”

Section: Discussionmentioning

confidence: 99%

The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

Papakostas

Petersen

Lebowitz³

et al. 2005

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

The objective of the present study was to examine the relationship between serum folate, vitamin B12, and homocysteine levels and the timing of clinical improvement to fluoxetine in major depressive disorder (MDD) patients. A total of 110 outpatients with MDD who responded to an 8-wk trial of fluoxetine had serum folate, B12, and homocysteine measurements at baseline (prior to fluoxetine initiation). Onset of clinical improvement was defined as a 30% decrease in Hamilton Depression Scale scores that led to a 50% decrease by week 8. Patients with low folate levels (0.05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

Papakostas

Petersen

Lebowitz³

et al. 2005

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

show abstract

“…A recent open study with SAMe [115] has also shown the usefulness of this augmenting agent in SSRI nonresponders. A placebo-controlled study of SAMe augmentation of imipramine had previously shown an acceleration of the response [116]. The availability of SAMe over the counter and the favorable side-effect profile (most-common side-effects are gastrointestinal symptoms and headaches) [115] have made this agent a relatively popular augmentation agent among MDD patients with residual symptoms.…”

Section: Augmentation Studiesmentioning

confidence: 99%

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

Fava

Rush

2006

Psychother Psychosom

138

View full text Add to dashboard Cite

Most patients with major depressive disorder (MDD) do not reach symptom remission. These patients with residual symptoms have worse function and worse prognosis than those who remit. Several augmentation and combination treatments are used to either increase the chances of achieving remission or to eliminate/minimize residual depressive symptoms. Evidence for these pharmacological approaches rests primarily on open, uncontrolled studies, and there are clearly not enough controlled studies. Clinicians should carefully weigh these different treatment options to increase their patients’ chances of achieving and sustaining remission from depression. This paper will review the pertinent studies and will propose a novel approach to improve practice involving the use of augmentation or combination strategies at the outset of initial treatment to primarily enhance the chances of remission through synergy and/or a broader spectrum of action. This novel approach could potentially enhance retention and/or increase remission rates since the lack of response with antidepressant monotherapy may lead many depressed patients with little or no benefit to drop out of treatment, precluding the subsequent use of augmentation or combination strategies altogether. In addition, the emergence of certain side-effects (e.g., agitation, insomnia) or the persistence of some initial baseline symptoms (e.g., anxiety, insomnia) may lead to premature discontinuation from monotherapy in the absence of concomitant use of augmenting pharmacological options targeting these symptoms.

show abstract

“…Antidepressant response was rapid and well tolerated [47]. Likewise, response to oral imipramine augmented with parenteral (intramuscular) SAMe was more rapid compared with the TCA alone [48].…”

Section: The Relevance Of S-adenosyl-methionine and Other Elements Ofmentioning

confidence: 97%

S-adenosyl-methionine in depression: A comprehensive review of the literature

Papakostas

Alpert²,

Fava³

2003

Curr Psychiatry Rep

View full text Add to dashboard Cite

As many as 29% to 46% of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.

show abstract

Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine

Cited by 59 publications

References 11 publications

The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

S-adenosyl-methionine in depression: A comprehensive review of the literature

Contact Info

Product

Resources

About